ABL1 is an inclusion eligibility criterion in 16 clinical trials for acute biphenotypic leukemia, of which 7 are open and 9 are closed. Of the trials that contain ABL1 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (3 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 14 clinical trials for acute biphenotypic leukemia, of which 6 are open and 8 are closed. Of the trials that contain AFF1 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 16 clinical trials for acute biphenotypic leukemia, of which 7 are open and 9 are closed. Of the trials that contain BCR status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (3 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 5 clinical trials for acute biphenotypic leukemia, of which 1 is open and 4 are closed. Of the trials that contain CBFB status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (0 open) [3].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 13 clinical trials for acute biphenotypic leukemia, of which 6 are open and 7 are closed. Of the trials that contain DEK status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

ELL is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain ELL status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 18 clinical trials for acute biphenotypic leukemia, of which 8 are open and 10 are closed. Of the trials that contain FLT3 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (4 open), 2 are phase 3 (0 open), and 1 is no phase specified (0 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 6 clinical trials for acute biphenotypic leukemia, of which 2 are open and 4 are closed. Of the trials that contain KIT status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

KMT2A is an inclusion eligibility criterion in 16 clinical trials for acute biphenotypic leukemia, of which 7 are open and 9 are closed. Of the trials that contain KMT2A status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (3 open), 2 are phase 3 (0 open), and 1 is no phase specified (0 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 17 clinical trials for acute biphenotypic leukemia, of which 10 are open and 7 are closed. Of the trials that contain MECOM status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 4 clinical trials for acute biphenotypic leukemia, of which 4 are open and 0 are closed. Of the trials that contain MLF1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

MLLT1 is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain MLLT1 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain MLLT10 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain MLLT3 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain MLLT4 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 5 clinical trials for acute biphenotypic leukemia, of which 1 is open and 4 are closed. Of the trials that contain MYH11 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (0 open) [3].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for acute biphenotypic leukemia, of which 4 are open and 0 are closed. Of the trials that contain NPM1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].

NRIP3 is an inclusion eligibility criterion in 12 clinical trials for acute biphenotypic leukemia, of which 5 are open and 7 are closed. Of the trials that contain NRIP3 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 13 clinical trials for acute biphenotypic leukemia, of which 6 are open and 7 are closed. Of the trials that contain NUP214 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 9 clinical trials for acute biphenotypic leukemia, of which 5 are open and 4 are closed. Of the trials that contain PBX1 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 17 clinical trials for acute biphenotypic leukemia, of which 10 are open and 7 are closed. Of the trials that contain RPN1 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (5 open), and 1 is no phase specified (0 open) [3].

RUNX1 is an inclusion eligibility criterion in 8 clinical trials for acute biphenotypic leukemia, of which 4 are open and 4 are closed. Of the trials that contain RUNX1 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 5 clinical trials for acute biphenotypic leukemia, of which 1 is open and 4 are closed. Of the trials that contain RUNX1T1 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 2 (0 open), and 1 is no phase specified (0 open) [3].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 9 clinical trials for acute biphenotypic leukemia, of which 5 are open and 4 are closed. Of the trials that contain TCF3 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

TET2 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is an inclusion eligibility criterion in 13 clinical trials for acute biphenotypic leukemia, of which 6 are open and 7 are closed. Of the trials that contain TP53 status and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (2 open), and 1 is no phase specified (0 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].